Here, our results further support the conclusion that eIF3G is a target for the anti-cancer properties of SAHA for the treatment of HCC and possibly other types of cancers and that its therapeutic benefit would be independent of a potential increased expression level of eIF3G (Figure S5B). The gene discussed is EIF3G; the disease is hepatocellular carcinoma.